Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02711852 · ClinicalTrials.gov registry record · Phase 2
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
A Phase 2 study, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02711852 is a Phase 2 study that has completed, run by SecuraBio. The registered enrollment target is 19 participants.
The verdict
NCT02711852, a Phase 2 study, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This was a long-term, continued treatment study that evaluated the long-term safety, clinical activity, and overall survival (OS) of duvelisib in individuals with hematologic malignancies that were previously treated with duvelisib in a previous sponsor-approved study.
Interventions
- DRUG Duvelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02711852
The ClinicalTrials.gov registry entry for NCT02711852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Duvelisib is the first listed.
NCT02711852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02711852 about?
NCT02711852 is a clinical study titled "A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)". This was a long-term, continued treatment study that evaluated the long-term safety, clinical activity, and overall survival (OS) of duvelisib in individuals with hematologic malignancies that were previously treated with duvelisib in a previous sponsor-approved study.
What is the current status of trial NCT02711852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-04. Estimated completion is 2020-05-04.
What interventions are being tested in trial NCT02711852?
The interventions under investigation include: Duvelisib (DRUG).
Who is sponsoring clinical trial NCT02711852?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.